Vaccine Adjuvants Market by Product, Route of Administration, Disease Type, Application, Application Category and Region - Global Forecast to 2027 - ResearchAndMarkets.com

The "Global Vaccine Adjuvants Market by Product (Particulate, Emulsions, Pathogen, Saponin), Route of Administration (Subcutaneous, Intramuscular), Disease Type (Infectious, Cancer), Application (Research, Commercial) & Application Category - Forecast to 2027" report has been added to ResearchAndMarkets.com's offering.

The vaccine adjuvants market is projected to reach USD 16 Billion by 2027 from USD 1.5 Billion in 2022, at a CAGR of 1.7% during the forecast period.

The growth of the market is projected to be driven by factors such as the rising prevalence of infectious diseases, increasing number of COVID-19 vaccines in the development pipeline, and increasing focus on immunization programs.

The adjuvant emulsions accounted for the largest share of the product segment in the vaccine adjuvants market in 2021

Adjuvant emulsions function by generating depots that can trap antigens at the injection site. This results in slow release to continue the stimulation of the immune system. The adjuvant emulsions segment accounted for the largest share of the market in 2021. The extensive use of adjuvant emulsions in COVID-19 and other infectious diseases and the rising prevalence of infectious diseases are driving the growth of the adjuvant emulsions segment during the forecast period.

The infectious disease segment accounted for the largest share of the disease type segment in the vaccine adjuvants market in 2021

The infectious diseases segment accounted for the largest share of the market in 2021. The large share of this segment can be attributed to the increasing prevalence of infectious diseases and the rising demand for new adjuvanted vaccines.

Key players in the vaccine adjuvants market include Prominent players in the global vaccine adjuvants market are GSK plc (UK), Dynavax Technologies (US), Novavax (US), Agenus Inc. (US), Croda International plc (UK), Seppic (France), OZ Biosciences (US), Phibro Animal Health Corporation (US), Associated British Foods plc (UK), InvivoGen (US), Merck KGaA (Germany), CSL Limited (Australia), Vertellus (US), Allergy Therapeutics (UK), Riboxx GmbH (Germany), CaPtivate Pharmaceuticals LLC (US), EuBiologics Co., Ltd. (South Korea), Pacific GeneTech Limited (US), Hawaii Biotech Inc. (US), and Vaxine Pty Ltd. (Australia).

Asia Pacific: The fastest-growing region in the vaccine adjuvants market

The Asia Pacific is estimated to be the fastest-growing segment of the market, owing to the increasing investments in the life sciences sector and rising awareness through conferences and symposiums. In this region, China and Japan are the largest markets while India is projected to grow at a highest CAGR during the forecast period.

Market Dynamics

Drivers

• Rising Prevalence of Infectious Diseases
• Increasing Use of Adjuvants in Vaccines
• Collaborations and Partnerships Among Market Players for Development of Vaccine Adjuvants
• Increasing Number of COVID-19 Vaccines in Development Pipeline
• Increasing Focus on Immunization Programs

Restraints

• Skepticism About Animal-Sourced Vaccine Adjuvants and Limitations on Shark Fishing

Opportunities

• Rising Funding for Vaccines and Infectious Disease Research Activities
• Development of Plant-Based Vaccine Adjuvants

Challenges

• Side Effects and High Toxicity of Adjuvants

Companies Mentioned

• Agenus Inc.
• Allergy Therapeutics
• CaPtivate Pharmaceuticals LLC
• Creative Diagnostics
• Croda International plc
• Csl Limited
• Dynavax Technologies
• Eubiologics Co., Ltd.
• Gsk plc
• Hawaii Biotech Inc.
• Invivogen
• Litevax Bv
• Merck KGaA
• Mukta Industries
• Novavax
• Oncovir, Inc.
• Oz Biosciences
• Pacific Genetech Limited
• Phibro Animal Health Corporation
• Riboxx GmbH
• Seppic (Subsidiary of Air Liquide Group)
• Spi Pharma (Subsidiary of Associated British Foods plc)
• Titermax Usa, Inc.
• Vaxine Pty Ltd.
• Vertellus

For more information about this report visit https://www.researchandmarkets.com/r/xx9mef